Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2011

View Archived Issues

HspB8 blocks autophagy in breast cancer cells, conferring resistance to tamoxifen

AV-7909 improves survival of ciprofloxacin-treated guinea pigs exposed to B. anthracis

AB-103 protects mice from SEB- and LPS-induced lethal shock

Bakuchiol cream is efficacious against acne in open-label trial

Etanercept demonstrates little activity to date in phase II trial in discoid lupus erythematosus

BAY-86-4367 effectively targets prostate tumors in preclinical study

Gentium completes defibrotide studies in veno-occlusive disease and prepares regulatory filings

GSK to launch new alli chewable tablet as weight loss aid

Phase IIb trial to compare delafloxacin to linezolid and vancomycin in ABSSSI

EMA grants orphan drug status to GT-038 in retinitis pigmentosa

Treatment begins in phase I elesclomol trial in acute myeloid leukemia

CytRx reports preclinical data on bafetinib in cancer-related bone loss

Elan and Boehringer Ingelheim to codevelop antibody-based therapeutics

R-Tech Ueno begins phase I trial to test RL-023's safety as therapy for eyelash hypotrichosis

Clinuvel completes phase II Scenesse trial in erythropoietic protoporphyria

Biovail Labs acquires Canadian license for Aczone from Allergen

Pervasis Therapeutics' Vascugel receives FDA fast track status

AMAG receives NON from Health Canada regarding Feraheme submission

Johnson & Johnson reports highlights fourth quarter 2010

Circassia acquires worldwide rights to psoriasis and atopic dermatitis treatment PAP-1

A.P. Pharma provides company update

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...